Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Ed Arce maintains Enanta Pharma (NASDAQ:ENTA) with a Buy and lowers the price target from $2...
JMP Securities analyst Roy Buchanan maintains Enanta Pharma (NASDAQ:ENTA) with a Market Outperform and lowers the price targ...
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(1.47) per share which missed the analyst consensus estimate of $(1.3...
JP Morgan analyst Eric Joseph maintains Enanta Pharma (NASDAQ:ENTA) with a Underweight and lowers the price target from $12 ...
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(1.58) per share which missed the analyst consensus estimate of $(1.2...
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per shar...
Expansion into Immunology with New Discovery Program of Oral KIT Inhibitors Addressing High Unmet Need in Chronic Spontaneous...
